ClinicalTrials.gg
Not yet recruitingNCT07941024Updated Nov 17, 2026

H.A.L.T. MAX Spectacle Lenses for High Myopia Control

An interventional study of H.A.L.T. MAX spectacles in High Myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Not yet recruiting. Open to participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
7 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.

Planned enrollment
25th of 36
112 · median 141
Started
2026
with 9 others
No phase
32 of 42
18 open now
Primary completion
2029-05
later than 21 of 21 live
Registered
42nd of 42
by date

Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, reaches primary completion later than 21 of the 21 other live ones, and was the 42nd registered.

Myopia

1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.

Browse Myopia studies →

Open to participants now

21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.

This study: 7 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, or all of them as a file.
02

Study summary

This study is intended to focus on children aged 7-14 years with high myopia and to use a 2-year, single-arm, prospective design in which participants wear H.A.L.T. MAX lenses for at least 12 hours per day for 2 consecutive years. By comparing changes in refractive error and other indicators, the study will evaluate the efficacy, safety, and wearing compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, thereby providing scientific evidence for public health efforts to delay myopia progression in highly myopic populations and for the formulation and implementation of programs to address the risk of blindness and visual impairment caused by high myopia.

03

Conditions studied

  • High Myopia

Browse trials for

Keywords

  • high myopia
04

Who can participate

Ages eligible
7 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 7-14 years old, regardless of gender.
  • Spherical equivalent refraction (SER) after cycloplegia ≤ -5.00 D and ≥ -9.00D.
  • Best corrected visual acuity in both eyes reached 0.8 (0.10 logMAR 6/7.5).
  • Anisometropia and astigmatism value ≤ 2.5 D.
  • Willing to wear only the spectacles provided by the investigator for a full day (>12 hours) without additional intervention during the study.
  • Able to sign the with the presence of parents or guardians.

Exclusion criteria

Exclusion Criteria:

  • Allergic or intolerant to cycloplegic drugs.
  • Exclude children on high dose atropine (1%) or red light therapy.
  • Any previous history of myopia control treatment in the previous 30 days, like low dose atropine, defocus spectacles, orthokeratology and acupuncture.
  • History or presence of an ocular disease, strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, and cataract.
  • History of eye surgery.
  • Eye or systemic diseases that may be associated with myopia, such as Marfan syndrome, retinopathy of newborns, diabetes, etc.
  • Anatomic or skin factors affecting the wearing of spectacles.
  • Other conditions unsuitable for inclusion (patients with excessive expectations for the effect of the defocus spectacle lenses or desires to try other myopia interventions).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years.

    Device: H.A.L.T. MAX spectacles

Interventions

  • DeviceH.A.L.T. MAX spectacles

    Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years.

06

What researchers measure

Primary outcomes

  1. SER change

    The proportion of of the right eye SER change ≤ -1.50D after 2 year of intervention.

    Time frame: 2 years

Secondary outcomes

  1. Axial change

    The proportion of the right eye axial change ≥ 0.68 mm after 2 year of intervention.

    Time frame: 2 years

Other outcomes

  1. Visual quality

    Visual aquity

    Time frame: 2 years

  2. Adaptation outcome

    Daily spectacles wearing time

    Time frame: 2 years

  3. Safety outcome

    Occurrence of adverse events

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2029, 30 months later.

Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 30 months is above that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 17, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
May 15, 2029
CompletionEst.
May 15, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941024
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
May 15, 2029 (estimated)
Completion
May 15, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion